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Abstract
Central core disease (CCD) is an inherited neuromuscular disorder characterised by central cores
on muscle biopsy and clinical features of a congenital myopathy. Prevalence is unknown but the
condition is probably more common than other congenital myopathies. CCD typically presents in
infancy with hypotonia and motor developmental delay and is characterized by predominantly
proximal weakness pronounced in the hip girdle; orthopaedic complications are common and
malignant hyperthermia susceptibility (MHS) is a frequent complication. CCD and MHS are allelic
conditions both due to (predominantly dominant) mutations in the skeletal muscle ryanodine
receptor (RYR1) gene, encoding the principal skeletal muscle sarcoplasmic reticulum calcium
release channel (RyR1). Altered excitability and/or changes in calcium homeostasis within muscle
cells due to mutation-induced conformational changes of the RyR protein are considered the main
pathogenetic mechanism(s). The diagnosis of CCD is based on the presence of suggestive clinical
features and central cores on muscle biopsy; muscle MRI may show a characteristic pattern of
selective muscle involvement and aid the diagnosis in cases with equivocal histopathological
findings. Mutational analysis of the RYR1 gene may provide genetic confirmation of the diagnosis.
Management is mainly supportive and has to anticipate susceptibility to potentially life-threatening
reactions to general anaesthesia. Further evaluation of the underlying molecular mechanisms may
provide the basis for future rational pharmacological treatment. In the majority of patients,




Central core disease (CCD) (MIM * 117000) [1] is an
inherited neuromuscular disorder defined by a) areas with
reduced oxidative activity running along the longitudinal
axis of the muscle fibre ("central cores") and b) clinical
features of a congenital myopathy.
CCD was originally reported in a family with congenital
hypotonia, non-progressive weakness and central areas of
amorphous appearance within muscle fibres stained with
the modified Gomori trichrome technique [2]. The term
CCD was introduced later [3] and reflects the characteris-
tic absence of oxidative enzyme activity in the core area
due to mitochondrial depletion [4].
Epidemiology
Epidemiological data are only available for the congenital
myopathies as a group but not for specific conditions. The
incidence of all congenital myopathies is estimated at
around 6.0/100,000 live births, or onetenth of all cases of
neuromuscular disorders [5]. Regional studies in North-
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ern Ireland [6] and Western Sweden [7] suggest a preva-
lence between 3.5 – 5.0/100,000 in a paediatric
population.
CCD is probably the most common congenital myopathy;
the condition is likely to be under recognised considering
that some individuals with suggestive clinical features and
an identical genetic background do not necessarily exhibit
the characteristic histopathological features, particularly
when biopsied at an early age.
Clinical description
Presentation of dominantly inherited CCD is typically in
infancy with hypotonia or in early childhood with motor
developmental delay [8]; however, marked clinical varia-
bility, often within the same family, has been recognised
[9-12]. Muscle stiffness and weakness on exertion are rec-
ognised presenting features [13,14]. More severe presenta-
tions within the range of the foetal akinesia sequence [15]
have been reported associated with recessive inheritance.
There is no association between the number of cores on
muscle biopsy and the degree of muscle weakness [16].
Distribution of weakness is typically proximal with prom-
inent involvement of the hip girdle and also axial muscles
[8]; rare patients may show focal wasting [17]. Inability to
bury eyelashes completely may be the only manifestation
of typically mild facial involvement. Bulbar involvement
is untypical in the dominant form and extra-ocular mus-
cle involvement has been considered a clinical exclusion
criterion by some authors [18]; however, both features
may be observed in the most severely affected neonates
due to recessive inheritance [15].
Orthopaedic complications are common in CCD [19] and
comprise congenital dislocation of the hips [20], scoliosis
which may be present from birth [12] and foot deformi-
ties including talipes equinovarus and pes planus [19].
Many affected individuals have marked ligamentous lax-
ity, occasionally associated with patellar instability [19],
whereas contractures other than tendon Achilles tightness
are rare.
Structural cardiac abnormalities other than mitral valve
prolapse have rarely been reported [13], but cardiomy-
opathies are not a feature of CCD associated with RYR1
mutations. Central cores on muscle biopsy have been
observed in a group of patients with hypertrophic cardio-
myopathy secondary to mutations in the beta-myosin
heavy chain (MYH7) gene, however, these patients typi-
cally do not have associated muscle weakness or any other
features of typical CCD [21]. Central and minicores in
association with a dilated cardiomyopathy may also rarely
been observed in patients with mutations in the skeletal
muscle α-actin (ACTA1) gene [22], more frequently asso-
ciated with nemaline myopathy.
Respiratory involvement in dominant CCD is exceptional
but may be severe in neonatal cases due to recessive RYR1
mutations [15].
Malignant hyperthermia, a pharmacogenetic disorder of
skeletal muscle characterised by an abnormal response to
muscle relaxants such as succinylcholine and volatile
anaesthetics, is a frequent complication [23-25]. Malig-
nant hyperthermia is a severe and occasionally fatal reac-
tion characterised by muscular rigidity, rhabdomyolysis,
rapid increase in body temperature and signs of general-
ised metabolic decompensation; survivors may suffer
severe renal and neurologic damage. Many patients with
CCD test positive for the malignant hyperthermia suscep-
tibility (MHS) trait on in vitro contracture test (IVCT)
[13,26] and should therefore be considered at risk for
malignant hyperthermia during general anaesthesia.
Almost all patients with CCD achieve the ability to walk
independently, except the most severe neonatal cases and
some of those with congenital dislocation of the hips
[27,28]. CCD typically follows a static or only slowly pro-
gressive course, even over prolonged periods of follow-up
[29]. Intermittent deterioration of symptoms has been
reported during or after pregnancy [30].
Serum creatine kinase (CK) activity is usually normal, but
may be elevated up to 6 to 14 times normal in rare cases
[11,31,32]. Muscle ultrasound often shows a striking
increase in echogenicity even in paucisymptomatic indi-
viduals [33]. A characteristic pattern of selective involve-
ment on muscle magnetic resonance imaging (MRI) has
been reported in patients with typical CCD [34] and is dis-
tinct from that observed in other congenital myopathies
such as nemaline myopathy [35]; muscle MRI may there-
fore be particularly useful for aiding genetic diagnosis in
cases with mixed pathologies featuring both cores and
rods [36,37].
Aetiology
CCD is due to mutations in the skeletal muscle ryanodine
receptor (RYR1) gene at chromosome 19q13.1, also
implicated in the malignant hyperthermia susceptibility
(MHS) trait, initially recognised as a familial autosomal
dominant trait by Denborough and Lovell [23] in Aus-
tralia.
An association between CCD and MHS had been sus-
pected early, as individuals with MHS may have central
cores on muscle biopsy [38], and patients with CCD may
be prone to malignant hyperthermia episodes [13,39,40].
The RYR1 gene had been considered as a candidate forOrphanet Journal of Rare Diseases 2007, 2:25 http://www.OJRD.com/content/2/1/25
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malignant hyperthermia based on the finding of a
founder mutation in the porcine isoform resulting in the
porcine stress syndrome (PSS), a naturally occurring ani-
mal model with almost identical clinical features [41].
Following demonstration of linkage to the human RYR1
locus in some families with MHS [42-45] and CCD [46-
48], subsequent identification of mutations in the RYR1
gene suggested that the two conditions are allelic disor-
ders [49-51].
RYR1 is organized in 106 exons [52] and encodes the skel-
etal muscle ryanodine receptor (RyR1), a large protein of
5037 amino acids visible on electron microscopy. RyR1 is
a ligand-gated release channel for Ca++ stored in the termi-
nal cisterna with a crucial role in excitation-contraction
(E-C) coupling by regulating cytosolic calcium levels.
RyR1 calcium release is primarily triggered by voltage-
induced conformational changes of the abutting dihydro-
pyridine receptor (DHPR), and secondarily by a number
of exogeneous and endogeneous effector molecules (for
review, [53]). RyR1 N-terminal portions are myoplasmic
and constitute the visible foot structure that interacts with
the DHPR, whereas the actual calcium release channel is
located in the C-terminal part of the protein [54,55].
More than 80 mutations have been identified in the RYR1
gene to date [56-63], most of them missense mutations. A
few small deletions [59,60,64] and cryptic splicing site
mutations [63,65] have been documented. The majority
of  RYR1  mutations associated with MHS or CCD
described to date were dominant mutations; homozygos-
ity or heterozygosity for RYR1 mutations has been previ-
ously documented in association with MHS [66,67] and
have been recently reported in a severe form of CCD pre-
senting with a foetal akinesia syndrome [15] and few mild
cases [16].
Genotype-phenotype correlations associated with muta-
tions in the RYR1 gene are complex and may be partly
explained by the degree of functional differentiation
within this large protein. Dominant RYR1  mutations
affecting the cytoplasmic N-terminal (MHS/CCD region
1, amino acids 35 – 614) and central (MHS/CCD region
2, amino acids 2163 – 2458) domains of the protein give
predominantly rise to the MHS phenotype [68], whereas
the CCD phenotype is closely associated with dominant
RYR1 C-terminal (MHS/CCD region 3, amino acids 4550
– 4940) mutations [16,58-61]. CCD-related dominant
RYR1 mutations affecting the N-terminal and central por-
tions of the protein and RYR1 C-terminal mutations giv-
ing rise to MHS represent exceptions to this rule but have
only been reported in a few families [50,51,69-71]. Reces-
sively inherited mutations are more widespread through-
out the RYR1  gene and appear to be more frequently
associated with the histopathological appearance of
Multi-minicore Disease (MmD) [27,63-65,72] rather than
CCD [16]. Data regarding the frequency of CCD-related
RYR1 mutations are currently emerging.
Although many mutations are private, the Arg4861Cys
substitution has been identified in three unrelated CCD
families and mutations affecting RYR1 exons 100 – 101
appear to be particularly common [16,61,62]. Since most
previous genetic studies in MHS and CCD were limited to
a partial screening strategy due to the large size of the
RYR1 gene, future studies involving the entire RYR1 cod-
ing sequence are likely to identify new mutational
hotspots.
Mutation-induced conformational changes of the RyR1
protein are thought to alter excitability and/or calcium
homeostasis within muscle cells, but the precise molecu-
lar mechanisms underlying genotype-phenotype correla-
tions associated with specific RYR1  mutations are
currently still emerging. Two models for receptor mal-
function have been proposed, depletion of sarcoplasmic
reticulum calcium stores with resulting increase in
cytosolic calcium levels ("leaky channel" hypothesis)
[73], and disturbance of excitation-contraction coupling
(E-C uncoupling hypothesis) [74]; these models are not
mutually exclusive and may be equally valid depending
on the specific effect of individual mutations on the struc-
turally complex RyR1 protein.
The functional effects of specific RYR1 mutations have
been studied in response to IVCT, in cultured myotubes
from patients and in various homologous and heterolo-
gous expression systems. Early studies already suggested
an association between specific RYR1 mutations and IVCT
response [75], and indicated a correlation between the
particular RYR1 gene mutation in a family and the severity
of MH or liability to CCD [26,76]. In vitro studies on
human myotubes demonstrated both increased [77,78]
and reduced [79,80] agonist sensitivity depending on the
precise location of the RYR1 mutation investigated. Stud-
ies on a RYR1 C-terminus mutation (I4898T) associated
with a severe CCD phenotype demonstrated reduced
intracellular calcium release without increasing the sensi-
tivity to caffeine or halothane [36] and a marked distur-
bance of excitation-contraction coupling [81]; the latter
may also apply for other C-terminal mutations [82]. Stud-
ies of RYR1  mutants expressed in myotubes of RYR1
knockout ("dyspedic") mice [83,84] indicate that mixed
MHS/CCD mutations are associated with increased chan-
nel activity sufficient to deplete sarcoplasmic reticulum
calcium stores, elevated intracellular calcium levels and
reduced maximum voltage gated calcium release [79],
whereas MH-only mutations appear to increase basal
release channel activity insufficiently to alter net sarco-
plasmic reticulum calcium content ("compensated leak").Orphanet Journal of Rare Diseases 2007, 2:25 http://www.OJRD.com/content/2/1/25
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Expression of a functional RyR1 protein in B-lymphocytes
has been recently described and offers a novel approach to
study the pathogenesis of RYR1 mutations in vitro. B-lym-
phocytes harbouring CCD-related RYR1 mutations show
depletion of sarcoplasmic reticulum stores secondary to
unprompted calcium release [59,85]; increased release of
inflammatory cytokines in the same study population
[86] may also point at a role of RYR1 in immunomodula-
tion.
Although most studies have confirmed the association
between CCD and mutations in the RYR1 gene, possible
genetic heterogeneity is indicated by recombination
events between CCD and RYR1 in one family [87], and
failure to identify a mutation despite screening of the
entire  RYR1  coding sequence in a severely affected
neonate with histopathologic and clinical features of CCD
[15].
Diagnostic methods
The diagnosis of CCD depends on the presence of typical
histopathological findings on muscle biopsy in combina-
tion with suggestive clinical features; muscle MR imaging
may complement clinical assessment.
Histochemical staining of muscle biopsy samples shows
the absence of oxidative and glycolytic enzymatic activity
from central core regions [4] (Figure 1). Central cores may
be single or multiple, central or eccentric [88,89], but
commonly run along a significant extent of the longitudi-
nal muscle fiber axis [90,91]; the latter feature distin-
guishes central cores most clearly from multi- or
minicores which share focal reduction of oxidative activity
as a common histopathological feature. Central cores are
typically found in type 1 fibres; marked type 1 predomi-
nance or uniformity and hypotrophy are typical and may
be the only abnormal features at presentation [89,92]. An
increase in internal nucleation is often associated and sub-
stantial increases in fat and connective tissue have been
described in some patients [89], corresponding to a
marked degree of increased signal intensity on muscle
MRI [35]. The degree of histopathologic changes may be
variable depending on sampling site and the age of the
patient.
Typical findings on electron microscopy include reduc-
tion or absence of mitochondria, variable degrees of
myofibrillar disorganisation and accumulation of abnor-
mal Z band material within the usually sharply demar-
cated core area [9]. Some ("structured") cores preserve a
degree of myofibrillar organisation and therefore retain
some ATPase activity; other ("unstructured") cores do not
and can be found in the same muscle biopsy [32,90]. The
sarcoplasmic reticulum and Ttubule structures may be
increased within the core area [93].
Abnormal expression of various sarcomeric and interme-
diate filament proteins, particularly desmin, has been
demonstrated within or around the core-area in a number
of immunohistochemical studies; corresponding to type 1
predominance on histochemical stains, slow myosin iso-
forms may be upregulated [89,94-96]. An antibody to the
actin cross-linking protein filamin C has been recently
identified as a strong but non-specific marker of central
cores [97].
In cases with equivocal histopathological features, muscle
MR imaging may complement clinical assessment and
indicate involvement of the RYR1 gene, as RYR1 C-termi-
nal mutations may be associated with a consistent pattern
of selective muscle involvement [35] (Figure 2) distinct
from that observed in other congenital myopathies such
as nemaline myopathy [34].
Differential diagnosis
The diagnosis of CCD is usually straightforward in cases
where clinical features are suggestive and typical central
cores are present on muscle biopsy; however, the typical
histopathological picture may only evolve over time and
may not always be present when muscle biopsy has been
performed at an early age. Also, core-formation is a non-
specific finding which may be observed in other clinical
contexts such as tenotomy, denervation ("target-fibers")
[98] or malignant hyperthermia susceptible individuals
without other features of a congenital myopathy [99]; it
Histopathologic appearance of typical central core disease Figure 1
Histopathologic appearance of typical central core 
disease: NADH-TR, transverse section from the rectus fem-
oris. Marked predominance of dark staining, high oxidative 
type 1 fibres with cores affecting the majority of fibres. 
Cores are typically well demarcated and centrally located 
(→), but may occasionally be multiple and of eccentric loca-
tion.Orphanet Journal of Rare Diseases 2007, 2:25 http://www.OJRD.com/content/2/1/25
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has to be emphasised that the presence of central cores on
muscle biopsy without associated weakness is not suffi-
cient to constitute a diagnosis of CCD.
The distinction from Multi-minicore Disease (MmD)
may be particularly difficult, as recent studies suggest a
histopathological continuum between the two conditions
in a subset of patients rather than distinct entities.
Although the great majority of MmD is caused by recessive
mutations in the selenoprotein N (SEPN1) gene [100],
recessive RYR1 mutations have been recently identified in
distinct subgroups of MmD [27,63,65,72]. However,
MmD-associated mutations give rise to clinical features
such as external ophthalmoplegia, bulbar involvement
and a moderate degree of respiratory impairment which
are not commonly observed in typical CCD.
Other conditions which may feature central cores on
muscle biopsy include hypertrophic cardiomyopathy
(HCM) associated with missense mutations in the β-
myosin heavychain gene, MYH7 [21]; in contrast to CCD,
muscle weakness is, however, exceptional and there are no
associated musculoskeletal deformities. Mutations in the
ACTA1 gene, more commonly associated with nemaline
myopathy, have been recently implicated in an autosomal
dominant myopathy with both central and minicores
[22]; however, some patients in this pedigree had an asso-
ciated cardiomyopathy, which is not a feature in RYR1-
related CCD.
The common occurrence of central cores and features of
other congenital myopathies such as nemaline rods or
minicores has been recognised for a long time, poses a
diagnostic challenge [37,101-103] and emphasises that
histopathological interpretation has to take into account
the clinical context.
Genetic counselling
Genetic counselling should be offered to all families and
individuals in whom a diagnosis of CCD has been made.
Although the majority of cases appear to be associated
with dominant inheritance, care should be taken in inter-
preting the mode of inheritance in isolated cases, as both
sporadic occurrence and, more recently, recessive inherit-
ance [16,27,72] have been documented; an unusually
severe presentation with antenatal onset in particular
should raise the possibility of a recessively inherited form
of CCD.
Molecular genetic confirmation of the diagnosis is possi-
ble by mutational analysis of the RYR1 gene; diagnostic
RYR1 screening has been established for malignant hyper-
thermia patients by a number of laboratories associated
with the European Malignant Hyperthermia Group
(EMHG) [104] but does require a modified approach for
patients with central core disease as many CCD-related
RYR1 mutations do not localise to known MH hotspots.
Technical difficulties associated with the large size of this
gene may be partly alleviated by focusing on the C-termi-
nal mutational hotspot [16,61,62], particularly exons 100
and 101, closely associated with the typical dominant
form of CCD; however, recessive inheritance due to com-
pound heterozygosity for two different RYR1 mutations
can not be excluded if only a partial screening strategy is
applied and sequencing of the entire RYR1  coding
sequence may be required in patients without confirmed
hotspot mutation.
Management
No curative treatment is currently available for CCD and
management is essentially supportive based on a multi-
disciplinary approach.
* Muscle involvement in the lower limbs in CCD secondary  to dominant RYR1 mutations Figure 2
* Muscle involvement in the lower limbs in CCD sec-
ondary to dominant RYR1 mutations: T1-weighted MR 
imaging, transverse sections of the proximal thigh (A-C) and 
the proximal lower leg (D-F) in an eleven (A) and a thirteen 
year old boy (B,E), and a twelve (C,F) and seventeen year old 
girl (D). In the thigh (A-C), there is marked increase in 
abnormal signal within vasti, sartorius and adductor magnus 
with relative sparing of rectus femoris, adductor longus, gra-
cilis and semitendinosus. In the lower leg, there is increase in 
abnormal signal in soleus (D-F), and – in more severe cases 
(E-F) – peroneal group and gastrocnemius medialis. Tibialis 
anterior and gastrocnemius lateralis are relatively spared. (VL 
= vastus lateralis, VI = vastus intermedius, VM = vastus medi-
alis, RF = rectus femoris, AL = adductor longus, AM = adduc-
tor magnus, S = sartorius, G = gracilis, St = semitendinosus). 
* Reprinted from Neuromuscul Disord 2004, 14: Jungbluth H, 
Davis MR, Muller C, Counsell S, Allsop J, Chattopadhyay A, 
Messina S, Mercuri E, Laing NG, Sewry CA, Bydder G, Mun-
toni F. Magnetic resonance imaging of muscle in con-
genital myopathies associated with RYR1 mutations. 
Pages: 785–790. Copyright Owner Elsevier, Copyright 
(2004), with permission from Elsevier".Orphanet Journal of Rare Diseases 2007, 2:25 http://www.OJRD.com/content/2/1/25
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Regular physiotherapy is aimed at the preservation of
muscle power and function and the prevention of contrac-
tures, particularly those of the tendon Achilles which are
commonly observed in CCD. Considering often promi-
nent axial involvement, exercises promoting endurance
and truncal stability such as swimming and riding [105]
may be particularly useful. Considering a tendency to
exercise-induced myalgia in CCD, exercises involving a
high-resistance load have to be approached with caution
and are probably not recommendable. If complications
such as congenital dislocation of the hips (CDH), talipes
equinovarus or scoliosis are present at birth or evolve in
the course of the disease, those may be managed surgically
at a centre with experience in the management of neu-
romuscular disorders once conservative approaches have
failed. As in other neuromuscular conditions, post-opera-
tive mobilization ought to be rapid in order to avoid
adverse effects of prolonged immobilization such as mus-
cle atrophy. In the most severe cases where walking can
not be achieved without additional support, independent
ambulation may be promoted by appropriate rehabilita-
tive measures such as provision of weight bearing calipers.
Clinically significant respiratory involvement is excep-
tional in typical cases of dominant CCD; however, consid-
ering the small risk of respiratory impairment, we would
advocate regular monitoring of respiratory capacity and
annual overnight oxygen saturation studies if forced vital
capacity (FVC) is less than 60% of the expected value, and
more frequently if FVC is less than 40% [106]. Respiratory
infections should be treated actively. In the most severely
affected, often recessive CCD cases with antenatal onset,
respiratory involvement may be severe enough to require
invasive ventilation [15,65]. Although in some of these
infants respiratory impairment may be life-limiting, oth-
ers appear to stabilise or even improve after a period of
ventilation; active treatment decision therefore ought to
be made on an individual basis applying the same criteria
as for other children with neonatally severe conditions.
An associated cardiomyopathy has not been reported in
typical CCD due to mutations in the RYR1 gene; however,
cardiomyopathies associated with mutations in the MYH7
[21] and the ACTA1 [22] genes may feature central cores
on muscle biopsy but do not share the typical clinical fea-
tures of CCD. Cardiac ultrasound studies therefore ought
to be considered in cases where clinical presentation is
unusual.
Patients with CCD are at risk of malignant hyperthermia,
an abnormal response to muscle relaxants such as succi-
nylcholine and volatile anaesthetics [24,25]. The anaes-
thetist ought to be aware of the diagnosis of CCD and
plan the anaesthesia accordingly, avoiding potentially
MH-triggering agents. Clinically manifest MH reactions
may be aborted by the RyR1 agonist Dantrolene if admin-
istered early in the course of a reaction. Not all patients
with CCD will be at risk of MH [36,72] and ideally the
MHS status ought to be determined by IVCT testing in
individual cases; however, this may not always be practi-
cal as the IVCT is not offered for young children and
involves an open muscle biopsy under general anaesthe-
sia. It may be more appropriate to assume MH susceptibil-
ity in CCD patients in the absence of firm evidence to the
contrary and discuss the issue with affected individuals
and their families accordingly.
In affected females, the potential for intermittent deterio-
ration of symptoms during or after pregnancy [30] ought
to be anticipated and discussed with the patient.
In addition to supportive management and prevention of
malignant hyperthermia reactions during general anaes-
thesia, the β-agonist salbutamol has been recently investi-
gated as a pharmacological agent in the treatment of CCD
with encouraging results [107]. However, results of this
pilot study will have to be validated in a larger rand-
omized controlled trial as a basis for future recommenda-
tion.
Prognosis
The typical form of dominantly inherited CCD is usually
associated with a mild to moderate degree of disability
and carries an overall favourable prognosis, although the
degree of severity may be variable, occasionally within the
same family. Apart from the most severe cases and some
of those with congenital orthopaedic complications
[27,28] almost all patients achieve the ability to walk
independently. The course of CCD is static or only slowly
progressive, even over prolonged periods of follow-up
[29].
In the most severely affected, often recessive CCD cases
with antenatal onset, respiratory impairment may be life-
limiting despite active management, although others
appear to stabilise or even improve after a period of venti-
lation [65].
Unresolved questions
CCD and the MHS trait are closely associated with muta-
tions in the RYR1 gene, but clear genotype-phenotype cor-
relations are still emerging. Screening of the entire RYR1
coding sequence in an increasing number of patients may
identify new mutational hotspots in future, and alleviate
the difficulties associated with the large size of this gene
by a more rationalised screening strategy.
Although the pathogenetic basis of CCD and the malig-
nant hyperthermia susceptibility trait is currently only
partially understood, available experimental evidenceOrphanet Journal of Rare Diseases 2007, 2:25 http://www.OJRD.com/content/2/1/25
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suggests a mutation-specific disruption of excitation-con-
traction-coupling and/or disturbance of intracellular cal-
cium homeostasis. Future work is likely to advance our
understanding of these key processes in contractile cells,
and to elucidate mutation-specific effects resulting in con-
genital myopathy phenotypes and/or malignant hyper-
thermia. Further understanding of the molecular basis of
CCD and MHS may also provide the basis for rational
pharmacological treatments. Unresolved questions con-
cern the pathogenesis of central cores, the impact of spe-
cific mutations on RyR1 assembly, the precise role of RyR1
in non-muscle cells such as B-lymphocytes and the effect
of mutations on those tissues, and other calcium depend-
ent signalling pathways other than E-C coupling.
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